Cargando…

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study

OBJECTIVE: Multiple factors predispose patients with cirrhosis to sepsis and/or bacteraemia and this has a high mortality rate. Within different geographical regions there are marked differences in the prevalence of infection with multidrug-resistant organisms (MDR). This study examined risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Amy L, Ratnasekera, Isanka U, Irvine, Katharine M, Henderson, Andrew, Powell, Elizabeth E, Valery, Patricia C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655566/
https://www.ncbi.nlm.nih.gov/pubmed/34876410
http://dx.doi.org/10.1136/bmjgast-2021-000695
_version_ 1784612100334682112
author Johnson, Amy L
Ratnasekera, Isanka U
Irvine, Katharine M
Henderson, Andrew
Powell, Elizabeth E
Valery, Patricia C
author_facet Johnson, Amy L
Ratnasekera, Isanka U
Irvine, Katharine M
Henderson, Andrew
Powell, Elizabeth E
Valery, Patricia C
author_sort Johnson, Amy L
collection PubMed
description OBJECTIVE: Multiple factors predispose patients with cirrhosis to sepsis and/or bacteraemia and this has a high mortality rate. Within different geographical regions there are marked differences in the prevalence of infection with multidrug-resistant organisms (MDR). This study examined risk factors for and outcomes of sepsis/bacteraemia in public hospital admissions with cirrhosis in the state of Queensland, Australia, over the last decade, along with the bacterial pathogens responsible and their antibiotic susceptibility profiles. DESIGN: A population-based retrospective cohort study of public hospital admissions was conducted from 1 January 2008 to 31 December 2017. Hospital admissions for patients with a diagnosis of cirrhosis were categorised by the presence or absence of sepsis/bacteraemia. Clinical and sociodemographic information including cirrhosis aetiology, complications and comorbidities, and in-hospital mortality were examined using bivariate and multivariate analyses. In patients with bacteraemia, the type and prevalence of bacteria and antibiotic resistance was assessed. RESULTS: Sepsis/bacteraemia was present in 3951 of 103 165 hospital admissions with a diagnosis of cirrhosis. Factors associated with sepsis/bacteraemia included disease aetiology, particularly primary sclerosing cholangitis (adj-OR 15.09, 95% CI 12.24 to 18.60), alcohol (adj-OR 2.90, 95% CI 2.71 to 3.09), Charlson Comorbidity Index ≥3 (adj-OR 3.54, 95% CI 3.19 to 3.93) and diabetes (adj-OR 1.87, 95% CI 1.74 to 2.01). Overall case-fatality rate among admissions with sepsis/bacteraemia was 27.7% (95% CI 26.3% to 29.1%) vs 3.7% (95% CI 3.6% to 3.8%) without sepsis/bacteraemia. In-hospital death was significantly associated with sepsis/bacteraemia (adj-OR 6.50, 95% CI 5.95 to 7.11). The most common organisms identified were Escherichia coli and Staphylococcus aureus, present in 22.9% and 18.1%, respectively, of the 2265 admissions with a positive blood culture. The prevalence of MDR bacteria was low (5.6%) CONCLUSION: Morbidity and mortality related to sepsis/bacteraemia in patients with cirrhosis remains a critical clinical problem.
format Online
Article
Text
id pubmed-8655566
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86555662021-12-27 Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study Johnson, Amy L Ratnasekera, Isanka U Irvine, Katharine M Henderson, Andrew Powell, Elizabeth E Valery, Patricia C BMJ Open Gastroenterol Hepatology OBJECTIVE: Multiple factors predispose patients with cirrhosis to sepsis and/or bacteraemia and this has a high mortality rate. Within different geographical regions there are marked differences in the prevalence of infection with multidrug-resistant organisms (MDR). This study examined risk factors for and outcomes of sepsis/bacteraemia in public hospital admissions with cirrhosis in the state of Queensland, Australia, over the last decade, along with the bacterial pathogens responsible and their antibiotic susceptibility profiles. DESIGN: A population-based retrospective cohort study of public hospital admissions was conducted from 1 January 2008 to 31 December 2017. Hospital admissions for patients with a diagnosis of cirrhosis were categorised by the presence or absence of sepsis/bacteraemia. Clinical and sociodemographic information including cirrhosis aetiology, complications and comorbidities, and in-hospital mortality were examined using bivariate and multivariate analyses. In patients with bacteraemia, the type and prevalence of bacteria and antibiotic resistance was assessed. RESULTS: Sepsis/bacteraemia was present in 3951 of 103 165 hospital admissions with a diagnosis of cirrhosis. Factors associated with sepsis/bacteraemia included disease aetiology, particularly primary sclerosing cholangitis (adj-OR 15.09, 95% CI 12.24 to 18.60), alcohol (adj-OR 2.90, 95% CI 2.71 to 3.09), Charlson Comorbidity Index ≥3 (adj-OR 3.54, 95% CI 3.19 to 3.93) and diabetes (adj-OR 1.87, 95% CI 1.74 to 2.01). Overall case-fatality rate among admissions with sepsis/bacteraemia was 27.7% (95% CI 26.3% to 29.1%) vs 3.7% (95% CI 3.6% to 3.8%) without sepsis/bacteraemia. In-hospital death was significantly associated with sepsis/bacteraemia (adj-OR 6.50, 95% CI 5.95 to 7.11). The most common organisms identified were Escherichia coli and Staphylococcus aureus, present in 22.9% and 18.1%, respectively, of the 2265 admissions with a positive blood culture. The prevalence of MDR bacteria was low (5.6%) CONCLUSION: Morbidity and mortality related to sepsis/bacteraemia in patients with cirrhosis remains a critical clinical problem. BMJ Publishing Group 2021-12-07 /pmc/articles/PMC8655566/ /pubmed/34876410 http://dx.doi.org/10.1136/bmjgast-2021-000695 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Hepatology
Johnson, Amy L
Ratnasekera, Isanka U
Irvine, Katharine M
Henderson, Andrew
Powell, Elizabeth E
Valery, Patricia C
Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title_full Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title_fullStr Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title_full_unstemmed Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title_short Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
title_sort bacteraemia, sepsis and antibiotic resistance in australian patients with cirrhosis: a population-based study
topic Hepatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655566/
https://www.ncbi.nlm.nih.gov/pubmed/34876410
http://dx.doi.org/10.1136/bmjgast-2021-000695
work_keys_str_mv AT johnsonamyl bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy
AT ratnasekeraisankau bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy
AT irvinekatharinem bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy
AT hendersonandrew bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy
AT powellelizabethe bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy
AT valerypatriciac bacteraemiasepsisandantibioticresistanceinaustralianpatientswithcirrhosisapopulationbasedstudy